|
|
|
|
ALS-2200, A Novel Once-daily Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity Over 7 Days in Treatmentnaïve
Genotype 1 (GT1) Patients
|
|
|
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
1Marcellin, P., 2Popa, S., 2Berliba, A., 2 Moscalu, I., 1Boyer, N., 3Kauffman, R.S., 3 Koziel, M., 3Garg, V., 4Tong, M.J., 5Chanda S.M., 5 Zhang, Q., 5Westland, C., 5Beigelman, L., 5Blatt, L.M., and 5Fry, J.
1. Hopital Beaujon, Clichy, France
2. Republican Clinical Hospital, Chisinau, Moldova
3. Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA
4. Liver Center, Huntington Medical Research Institutes, Pasadena, CA, USA
5. Alios BioPharma, South San Francisco, CA, USA
|
|
|
|
|
|
|